ReviewBone marrow transplantation2026
Usage of rabbit anti-thymocyte / anti-T-lymphocyte globulins (ATG / ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee.
Review in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.Bone marrow transplantation · 2026Guideline
- Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.American journal of hematology · 2026Article
- Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabbit anti-thymocyte globulin (ATG) and anti-T-lymphocyte globulin (ATLG) are widely used in allogeneic hematopoietic cell transplantation (allo-HCT) to prevent graft rejection and reduce the risk of graft-versus-host disease. Despite their broad application, clinical practice varies substantially in terms of product selection, dosing, and timing. Distinct differences in manufacturing, pharmacokinetics, and immunological effects between ATG and ATLG complicate efforts to standardize their use across transplant platforms. This review presents the most recent insights into the pharmacology, mechanisms of action, clinical efficacy, and toxicity profiles of both agents. It highlights their differential impact across various allo-HCT settings. Key topics such as re-exposure, immune reconstitution, adverse events, and individualized dosing strategies guided by pharmacokinetic modeling are discussed. These analyses informed consensus recommendations developed through a dedicated expert workshop within the EBMT to support optimized, context-specific use of rabbit ATG and ATLG in allo-HCT for hematologic malignancies.
Indexed as
Identifiers
41298854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.